Other News To Note
Monday, January 3, 2011
Swedish Orphan Biovitrum AB, of Stockholm, Sweden, announced that it has returned full development rights for its immune thrombocytopenic purpura (ITP) treatment and for hemolytic disease in newborn (HDN) prophylaxis to Symphogen A/S, of Copenhagen, Denmark, co-developer of Sym001, which is currently in Phase II trials for treatment of ITP and in anti-D prophylaxis to prevent HDN.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.